AI Science Tracker

Ro5 (AI Chemistry)

1 discovery from 2024

Discoveries

Prospective deep-learning screen identifies nanomolar IRAK1 inhibitor scaffolds

Ro5's prospective HydraScreen structure-based deep-learning screen ranked compounds for IRAK1 and was evaluated against a 47,000-compound robotic high-throughput screen. The study reports that 23.8% of IRAK1 hits were in HydraScreen's top 1% and identifies three nanomolar scaffolds, two described in the abstract as novel IRAK1 candidates.

Technology: HydraScreen structure-based deep-learning virtual screening, with SpectraView knowledge-graph target evaluation

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: The study reports that 23.8% of IRAK1 hits were in HydraScreen's top 1% and identifies three nanomolar scaffolds, two described in the abstract as novel IRAK1 candidates. The new candidate experiments were conducted within the Ro5/Strateos discovery collaboration.
  • Still unknown: This is prospective early-stage hit identification, not drug development or disease efficacy. The assay validated kinase inhibition in vitro. Authors are affiliated with the companies that developed the tools. The abstract describes two scaffolds as novel candidates, while detailed similarity analysis indicates one of three nanomolar scaffolds had a similar known active; do not call all hits unprecedented.
  • AI role: SpectraView selected IRAK1 as the study target; HydraScreen scored docked ligand-pose ensembles to rank compounds before prospective screening. Researchers compared rankings with automated high-throughput assay results from a 47,000-compound library and reported nanomolar IRAK1 hit scaffolds, two described as novel candidates.

Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC11566907/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: at percentile 77 of works of the same type, year and subfield (OpenAlex work metrics, 9 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open the interactive profile for the timeline, or browse all organizations and model families.